BUZZ-GE Healthcare shares fall after $945 million Sofie Biosciences acquisition deal
路透社2026/10/05 14:11October 5th - ** Medical device manufacturer GE HealthCare (GEHC.O) shares fell over 1%, closing at $63.55. ** The company announced it would acquire privately held Sofie Biosciences for $945 millions in cash. This acquisition will grant GE HealthCare rights to FAPI-74 in the U.S., an experimental PET imaging agent in late-stage clinical trials, used for the detection of various cancers. The company already holds rights to the product outside the U.S. GE HealthCare stated that after the transaction, which is expected to close in the first half of 2027, Sofie will continue manufacturing products for its existing clients, including other radiopharmaceutical companies. Among 21 brokers, 15 have given the stock a "Buy" or higher rating, while 6 have rated it "Hold"; the median price target is $85, according to data compiled by LSEG. Including today's fluctuations, the stock has fallen by 22.5% so far this year. (For the convenience of non-English speakers, Reuters has automatically translated its report into several other languages. Since automated translation may contain inaccuracies or lack context, Reuters does not guarantee the accuracy of the automated texts and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of the automated translation feature.)
October 5 - ** Shares of medical device manufacturer GE HealthCare (GEHC.O) fell more than 1%, closing at $63.55
** The company announced it will acquire privately held Sofie Biosciences (link) for $945 million in cash
** The acquisition will give the company the U.S. rights to FAPI-74, a late-stage clinical trial investigational PET imaging agent used for detecting multiple types of cancer
** The company already owns the rights to this product outside the U.S.
** The company stated that after the deal is completed (expected in the first half of 2027), Sofie will continue to manufacture products for existing customers, including other radiopharmaceutical companies
** Out of 21 brokers, 15 rate the stock as “buy” or higher, and 6 give it a “hold” rating; the median target price is $85—data compiled by LSEG
** After accounting for intraday volatility, the stock has fallen 22.5% so far this year
(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"
Crypto prices
More
